1. Scrip
  2. >>Therapy Areas

Video Interview: Corbus Sees 2016 As Pivotal Year

 
• By Mike Ward

With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.

With key clinical data readouts expected at the end of 2016 and the start of 2017, Corbus Pharmaceuticals Holdings Inc.'s CEO Dr. Yuval Cohen expects the next 12 months to be pivotal for the rare inflammatory disease company. Speaking to Informa Pharma Insights global director of content Mike Ward, Cohen reveals that the company expects to report Phase II data for Resunab, its synthetic endocannabinoid-mimetic compound that binds to the CB2 receptor, in both cystic fibrosis and systemic sclerosis. Phase II data for Resunab in dermatomyositis will be available 1Q 2017.

This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.